Ametek (AME) Q3 2025 earnings review
EMG's Explosive Rebound Drives Record Quarter, Guidance Raised Again
AMETEK delivered a powerful Q3, beating expectations with revenue growth accelerating to 11% and adjusted EPS growing 14% YoY. The performance was driven by a dramatic turnaround in the Electromechanical Group (EMG), which surged 12% organically as the destocking cycle in its medical and automation businesses ended decisively. This strength more than compensated for the flat organic performance in the larger Electronic Instruments Group (EIG), which continues to see project delays in its Process markets. Confident in the momentum, management raised full-year EPS guidance for the second consecutive quarter, though the Q4 forecast implies a moderation in earnings growth.
🐂 Bull Case
The end of the destocking cycle has unleashed pent-up demand in the EMG segment, which posted 12% organic growth and a massive 250 basis point margin expansion. Strong orders at Paragon Medical confirm the recovery is robust.
Overall organic orders grew 7% in the quarter, outpacing sales and leading to a record backlog of $3.54 billion. Management noted September was the strongest month of the year, suggesting positive momentum heading into Q4.
🐻 Bear Case
The company's largest segment, EIG, reported flat organic growth. This weakness, concentrated in the Process businesses, is being masked by acquisitions. Ongoing trade friction continues to cause project delays.
The Q4 guidance for adjusted EPS implies YoY growth of just 2-4% (or 6-9% adjusted for tax). This is a marked deceleration from Q3's 14% growth rate, signaling a tougher comparison and potentially moderating profit momentum.
⚖️ Verdict: 🟢
Bullish. The sharp, broad-based recovery in the EMG segment is a powerful new growth driver that offsets the sluggishness in EIG. With strong order flow, expanding margins, and a proven M&A engine, the company is demonstrating excellent operational execution. The moderating Q4 EPS guidance is a point of caution, but the underlying operational momentum is compelling.
Key Themes
Electromechanical Group (EMG) Roars Back to Life
The EMG segment was the standout performer, reversing its recent trend with 12% organic sales growth. Management confirmed that the destocking cycle in its Automation and Paragon Medical businesses is now over. This volume recovery, combined with operational efficiencies, drove operating margins up sharply by 250 basis points YoY to 25.4%, a record for the segment.
Electronic Instruments Group (EIG) Remains Sluggish Organically
While total EIG sales grew 10%, this was entirely due to acquisitions like FARO. Organic sales were flat, contradicting the positive headline numbers. Management cited continued caution in Process markets, where trade uncertainty is leading to slower customer decision-making and project delays. This segment's core growth has now been flat or negative for at least three consecutive quarters.
Strong Orders and Record Backlog Provide Visibility
AMETEK's order book strengthened significantly, with total orders up 13% and organic orders up 7%. This resulted in a book-to-bill ratio above 1.0 and pushed the company's backlog to a record $3.54 billion. Management noted that September was the strongest month of the year for both sales and orders, indicating solid momentum entering the final quarter.
China and Trade Friction Causing Delays
The call transcript revealed specific weakness in Asia driven by China, where sales were down. Management noted that 'tariff games' are causing customers to delay purchases while they attempt to renegotiate pricing with government entities to cover new tariffs. This highlights a tangible impact from the trade environment that is weighing on the Process businesses within EIG.
Innovation Drives Differentiation
The company continues to invest in R&D, reflected in a strong Vitality Index of 26% (sales from new products). Management highlighted several innovations, including a new AI-powered inspection camera from Virtek for complex manufacturing, advanced receivers from NSI-MI for defense and satellite systems, and an award-winning clinical communication platform from Rauland. These investments support pricing power and long-term growth.
M&A Strategy Continues to Execute
Strategic acquisitions remain the primary focus for capital deployment. The recent acquisition of FARO Technologies is integrating well and hit its financial targets for the quarter. With a strong balance sheet (net debt-to-EBITDA of 0.9x) and over $2 billion in liquidity, AMETEK is well-positioned to continue pursuing deals from its robust pipeline.
Other KPIs
Improved by 90 basis points from 26.1% a year ago, excluding recent acquisitions. This demonstrates strong operational execution and pricing discipline, as the company confirmed it successfully offset inflation and tariff impacts with a positive spread. Margin expansion was particularly strong in the recovering EMG segment.
The company generated strong free cash flow of $420 million, converting 113% of net income. For the full year, management expects a robust conversion rate of 110-115%. This consistent cash generation is the engine that funds the company's M&A strategy and shareholder returns.
Guidance
Stable. This is a raise from the prior range of $7.06 - $7.20. The new midpoint implies 7.5% YoY growth over 2024's adjusted EPS, reflecting management's increased confidence following the strong Q3 performance.
Stable / Slight Deceleration. Guidance implies a continuation of the strong growth seen in Q3 (+11%), though at a slightly lower rate. This suggests the positive momentum, largely from the EMG rebound and M&A contributions, is expected to persist through year-end.
Decelerating. The midpoint of $1.925 implies just 3% YoY growth over Q4 2024's $1.87. Management noted this is partly due to a tough comparison against a lower-than-normal tax rate last year. Adjusting for that, growth would be 6-9%, which is still a clear deceleration from Q3's 14% growth rate.